Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amdl
Amdl files preliminary proxy statement with U.S. SEC regarding Jade acquisition
July 4th, 2006
Amdl, Inc., (ADL) a developer and marketer of tests for the early detection of cancer and other serious diseases, has filed a 14(a) Preliminary Proxy Statement with the SEC for review and comment. This proxy statement is related to the acquisition of Jade Pharmaceutical, Inc., and other corporate matters. Gary L. Dreher, CEO, indicated that "when approved by the SEC, the Proxy Statement should allow Amdl to hold a special in lieu of annual stockholders meeting to vote upon and complete the Jade Pharmaceutical acquisition by the end of the third quarter of 2006." Dreher further explained that "the acquisition of Jade Pharmaceutical will allow Amdl to...
Source: Pharma Law Weekly (2006-07-04)
|
